OncoMatch/Clinical Trials/NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Is NCT06137144 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AZD3470 for lymphoma.
Treatment: AZD3470 — This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hodgkin Lymphoma
Biomarker criteria
Required: MTAP expression (central MTAP expression determination required; no threshold specified)
must provide FFPE baseline tumour tissue to meet the minimum tissue requirement for central MTAP expression determination
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: antibody-drug conjugate (Brentuximab Vedotin)
must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL
Must have received: anti-PD-1 therapy
must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL
Cannot have received: MAT2A inhibitor
Prior treatment with a MAT2A inhibitor
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
Liver function
Cardiac function
Mean resting QTcF > 470 msec or clinically important abnormalities in rhythm (ventricular arrhythmias and uncontrolled atrial fibrillation); factors that increase the risk of QTc prolongation or risk of arrhythmic events; cardiac procedures or conditions within the last 6 months: CABG, PCI or heart valve intervention vascular stent implantation, acute coronary syndrome / myocardial infarction, uncontrolled angina pectoris, use of therapeutic anti-coagulation for treatment of active thromboembolic events; severe valvular heart disease; congestive heart failure Grade II to Grade IV; prior or current cardiomyopathy; uncontrolled hypertension; brain perfusion problems such as haemorrhagic or thrombotic stroke (including transient ischemic attacks)
Adequate organ and bone marrow function. Cardiac criteria: see exclusion criteria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Miami, Florida
- Research Site · Atlanta, Georgia
- Research Site · Boston, Massachusetts
- Research Site · Philadelphia, Pennsylvania
- Research Site · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06137144 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MAT2A inhibitor, PRMT5 inhibitor disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages